Specialist-level retinopathy screening, anywhere.
EYELYTIX analyzes retinal images with AI, classifies diabetic retinopathy severity in seconds, and produces a clear clinical report, so more patients can be screened earlier.
Bring early screening to more patients.
Diabetic retinopathy is most treatable when it is caught early, yet specialist screening cannot reach everyone who needs it. EYELYTIX extends that reach: it brings specialist-level analysis to the point of care, so far more patients can be screened, sooner.
How it works.
-
01
Capture
A retinal image is taken at the point of care.
-
02
Analyze
AI analyzes the image and classifies diabetic retinopathy severity in seconds.
-
03
Report
EYELYTIX produces a clear clinical report with the severity classification.
-
04
Clinician sign-off
A qualified professional reviews and confirms the result before it guides care.
What EYELYTIX offers.
Fast
Severity classification in seconds, at the point of care.
Clear
A structured clinical report a clinician can act on.
Accessible
Brings screening capability to more settings and more patients.
Clinician-confirmed
Every result is reviewed and signed off by a qualified professional.
Built for real screening settings.
EYELYTIX is designed to fit into diabetes care, primary care, and screening programs, producing structured, reviewable output that supports the clinician's decision.
Human-led by design.
AI performs the analysis; a qualified professional confirms every result before it informs care. EYELYTIX runs on secure, compliance-ready workflows with clear records.
Extend retinopathy screening to more patients.
Book a consultation to see how EYELYTIX fits your screening program.